enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website
enVVeno Medical has launched a recap website showcasing its participation at the 51st Annual VEITH Symposium. The website features interviews with patients and Principal Investigators from the VenoValve U.S. Pivotal Trial, along with presented data. The company's CEO, Robert Berman, emphasized the importance of sharing first-hand experiences from physicians and patients. VenoValve is positioned as a potential first-in-class surgical replacement venous valve for severe deep venous CVI, targeting approximately 2.5 million potential new U.S. patients annually. The company is also developing enVVe, a transcatheter-based replacement venous valve.
enVVeno Medical ha lanciato un sito web di riepilogo che mette in evidenza la sua partecipazione al 51° Simposio Annuale VEITH. Il sito presenta interviste con pazienti e Investigatori Principali del VenoValve U.S. Pivotal Trial, insieme ai dati presentati. Il CEO dell'azienda, Robert Berman, ha sottolineato l'importanza di condividere esperienze dirette da medici e pazienti. VenoValve si posiziona come una potenziale valvola venosa sostitutiva di prima classe per la grave insufficienza venosa cronica profonda, mirata a circa 2,5 milioni di potenziali nuovi pazienti negli Stati Uniti ogni anno. L'azienda sta anche sviluppando enVVe, una valvola venosa sostitutiva basata su un approccio transcatetere.
enVVeno Medical ha lanzado un sitio web resumen para mostrar su participación en el 51º Simposio Anual VEITH. El sitio presenta entrevistas con pacientes e Investigadores Principales del VenoValve U.S. Pivotal Trial, junto con los datos presentados. El CEO de la compañía, Robert Berman, enfatizó la importancia de compartir experiencias de primera mano de médicos y pacientes. VenoValve se posiciona como una posible válvula venosa reemplazo de primera clase para la grave insuficiencia venosa crónica profunda, con un objetivo de aproximadamente 2,5 millones de nuevos pacientes potenciales en EE.UU. anualmente. La compañía también está desarrollando enVVe, una válvula venosa reemplazo basada en un enfoque transcatéter.
enVVeno Medical는 제51회 VEITH 심포지엄 참여를 보여주는 요약 웹사이트를 출시했습니다. 이 웹사이트는 VenoValve U.S. Pivotal Trial의 환자 및 주요 연구자와의 인터뷰와 함께 발표된 데이터를 특징으로 합니다. 회사의 CEO인 로버트 버먼은 의사와 환자의 직접 경험을 공유하는 것의 중요성을 강조했습니다. VenoValve는 심각한 심부 정맥 만성 정맥 기능 부전(CVI)을 위한 잠재적인 1세대 수술용 대체 정맥 판막으로 자리 잡고 있으며 매년 약 250만 명의 새로운 미국 환자를 대상으로 합니다. 회사는 또한 enVVe라는 수술용 대체 정맥 판막을 개발 중입니다.
enVVeno Medical a lancé un site Web récapitulatif présentant sa participation au 51ème Symposium Annuel VEITH. Le site présente des interviews avec des patients et des Investigateurs Principaux de l'Essai Pivotal VenoValve U.S., ainsi que les données présentées. Le PDG de l'entreprise, Robert Berman, a souligné l'importance de partager des expériences vécues par des médecins et des patients. VenoValve est positionnée comme une potentielle valve veineuse chirurgicale de première classe pour une insuffisance veineuse chronique sévère, ciblant environ 2,5 millions de nouveaux patients potentiels chaque année aux États-Unis. L'entreprise développe également enVVe, une valve veineuse de remplacement basées sur un système de cathéter.
enVVeno Medical hat eine Zusammenfassungswebsite gestartet, die die Teilnahme am 51. jährlichen VEITH-Symposium präsentiert. Die Website enthält Interviews mit Patienten und Hauptforschern der VenoValve U.S. Pivotal Trial, sowie die präsentierten Daten. Der CEO des Unternehmens, Robert Berman, betonte die Wichtigkeit, direkte Erfahrungen von Ärzten und Patienten zu teilen. VenoValve positioniert sich als potenzielle erstklassige chirurgische Ersatzvenenklappe für schwere chronische venöse Insuffizienz (CVI), die jährlich etwa 2,5 Millionen potenzielle neue Patienten in den USA anspricht. Das Unternehmen entwickelt auch enVVe, eine katheterbasierte Ersatzvenenklappe.
- Large market opportunity with 2.5 million potential annual U.S. patients
- Development of next-generation transcatheter-based valve (enVVe) could expand market reach
- Building strong physician and patient advocacy network for post-FDA approval commercialization
- Product still pending FDA approval
- Operating in a market with $4 billion annual healthcare costs
Insights
The launch of a VEITH symposium recap website, while showcasing patient testimonials and trial investigator perspectives, represents a routine marketing update without material financial or regulatory impact. While the company's VenoValve device addresses a significant market opportunity for Chronic Venous Insufficiency (CVI) treatment - with an estimated
The website launch is primarily focused on building physician and patient advocacy networks ahead of potential FDA approval. Though this groundwork is important for future commercialization, it does not represent a material development that would significantly impact investor decision-making at this time.
Interviews with participating patients from the VenoValve® U.S. Pivotal Trial
Webcast replay from with the presenting Primary Investigators
Presentation with data from the VenoValve U.S. Pivotal Trial
Access the Recap Website Here!
IRVINE, CA / ACCESSWIRE / November 27, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the launch of a recap website which highlights the Company's participation at the recently held 51st Annual Vascular and Endovascular, Techniques and Horizons (VEITH) Symposium. Materials accessible on the recap website include interviews with two patients and two Principal Investigators who participated in the VenoValve U.S. Pivotal Trial as well as data presented at the symposium.
"While our data is compelling, we think it is equally important to hear the stories behind the data from both physicians and patients who have first-hand experience with the VenoValve," said Robert Berman, enVVeno Medical's Chief Executive Officer. "It is physicians and patients that will ultimately drive our commercial success following FDA approval. This is the second group of patients and third group of primary investigators whose perspectives we have made available. It takes an organic network of physician and patient advocates for a new device to succeed and anyone who takes the time to engage with these materials will recognize the strong foundation we've established."
Access the enVVeno Medical VEITH Symposium Recap Site at envveno.com/veith-2024
Severe, deep venous Chronic Venous Insufficiency (CVI) is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. Estimates indicate that CVI costs the U.S. healthcare system in excess of
The VenoValve® is a potential first-in-class, surgical replacement venous valve for patients with severe deep venous CVI. The Company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for the VenoValve. The Company is also developing enVVe®, a next-generation, transcatheter based replacement venous valve, that could appeal to an even larger market in terms of both patients and physicians.
About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the SAVVE U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe.
Cautionary Note on Forward-Looking Statements
This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
###
INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
NVNO@jtcir.com
(908) 824-0775
SOURCE: enVVeno Medical Corporation
View the original press release on accesswire.com
FAQ
What is the market size for VenoValve (NVNO) in the United States?
What products is enVVeno Medical (NVNO) currently developing?
What was announced at the 2024 VEITH Symposium by enVVeno Medical (NVNO)?
